PMID- 37795033
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231030
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Locally advanced head and neck squamous cell carcinoma treatment efficacy and 
      safety: a systematic review and network meta-analysis.
PG  - 1269863
LID - 10.3389/fphar.2023.1269863 [doi]
LID - 1269863
AB  - Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 3% of 
      new cancer cases and 3% of all deaths worldwide. Most HNSCC patients are locally 
      advanced (LA) at diagnosis. The combination of radiotherapy (RT), chemotherapy, 
      targeted therapy, and immunotherapy are the primary LA-HNSCC treatment options. 
      Nevertheless, the choice of optimal LA-HNSCC treatment remains controversial. We 
      systematically searched public databases for LA-HNSCC-related studies and assess 
      treatment effectiveness and safety by assessing the objective response rate 
      (ORR), >/=3 adverse events (AEs), overall survival (OS), progression-free survival 
      (PFS), disease-free survival (DFS), local-region control (LRC), and 
      disease-specific survival (DSS). 126 randomized controlled clinical trials (RCTs) 
      were included in this study. We show that concurrent RT with nimotuzumab or 
      conventional concurrent chemo-radiotherapy (CCRT) had significantly better 
      efficacy and long-term survival without increasing AEs than RT alone. Accelerated 
      fractionated radiotherapy (AFRT) showed better efficiency than conventional 
      fractionated RT, although it had higher AEs. In addition, concurrent cetuximab 
      combined with RT failed to show a significant advantage over RT alone. Trial 
      registration: PROSPERO CRD42022352127.
CI  - Copyright (c) 2023 Wang, Zheng, Zhang, Bian, Bao, Xin and Jiang.
FAU - Wang, Huanhuan
AU  - Wang H
AD  - Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First 
      Hospital of Jilin University, Changchun, China.
AD  - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, 
      Changchun, China.
FAU - Zheng, Zhuangzhuang
AU  - Zheng Z
AD  - Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First 
      Hospital of Jilin University, Changchun, China.
AD  - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, 
      Changchun, China.
FAU - Zhang, Yangyu
AU  - Zhang Y
AD  - Division of Clinical Research, The First Hospital of Jilin University, Changchun, 
      China.
FAU - Bian, Chenbin
AU  - Bian C
AD  - Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First 
      Hospital of Jilin University, Changchun, China.
AD  - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, 
      Changchun, China.
FAU - Bao, Jindian
AU  - Bao J
AD  - Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First 
      Hospital of Jilin University, Changchun, China.
AD  - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, 
      Changchun, China.
FAU - Xin, Ying
AU  - Xin Y
AD  - Key Laboratory of Pathobiology, Ministry of Education, Jilin University, 
      Changchun, China.
AD  - College of Basic Medical Sciences, Jilin University, Changchun, China.
FAU - Jiang, Xin
AU  - Jiang X
AD  - Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First 
      Hospital of Jilin University, Changchun, China.
AD  - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, 
      Changchun, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230919
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10546034
OTO - NOTNLM
OT  - accelerated fractionated radiotherapy
OT  - concurrent chemo-radiotherapy
OT  - locally advanced head and neck squamous cell carcinoma
OT  - meta-analysis
OT  - radiotherapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/10/05 06:43
MHDA- 2023/10/05 06:44
PMCR- 2023/09/19
CRDT- 2023/10/05 04:03
PHST- 2023/07/31 00:00 [received]
PHST- 2023/09/04 00:00 [accepted]
PHST- 2023/10/05 06:44 [medline]
PHST- 2023/10/05 06:43 [pubmed]
PHST- 2023/10/05 04:03 [entrez]
PHST- 2023/09/19 00:00 [pmc-release]
AID - 1269863 [pii]
AID - 10.3389/fphar.2023.1269863 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Sep 19;14:1269863. doi: 10.3389/fphar.2023.1269863. 
      eCollection 2023.